Loading the company…
Loading the company…
Families: Skin substitutes & wound grafts, Bone graft & orthobiologics, Lumbar fusion, Hernia repair.
All companies · Product and company coverage
In 2025, Geistlich Pharma reported engagement with 1,532 surgeons and other clinicians in the states MedaRep covers, worth $257K in consulting, speaking, meals and travel for its device products, the most in Massachusetts ($68K to 85). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Massachusetts ($68K, 85 engaged), California ($30K, 307 engaged), Texas ($25K, 119 engaged), Pennsylvania ($24K, 38 engaged), New York ($15K, 182 engaged).
In the last ten years FDA made 10 decisions for Geistlich Pharma (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 4 procedure families, the most in 2026 (3). The latest was on 2026-06-02.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 5 |
| Bone graft & orthobiologics | 4 |
| Lumbar fusion | 4 |
| Hernia repair | 1 |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Geistlich Pharma.